


wherein, R_{01} and R_{02} are each independently a hydrogen atom, a trimethylsilyl group, a triethylsilyl group, a t-butyldimethylsilyl group, an acetyl group, a methoxymethyl group or a tetrahydro-4H-pyran-2-yl group;

Z is represented by formula (1-5),



in the above formula (1-5),

R_{51} expresses $-\text{CONR}_{511}\text{R}_{512}$, $-\text{COR}_{513}$ or $-\text{C}(\text{OH})\text{R}_{514}\text{R}_{515}$, wherein R_{511} and R_{512} are identical to or different from each other, and they are a hydrogen atom or a C_1 - C_4 alkyl group, or both the members together express a nitrogen-containing C_3 - C_8 alkyl ring or a morpholino group in cooperation with the nitrogen atom to which they are bonded; and R_{513} , R_{514} and R_{515} are identical to or different from each other, and they express a C_1 - C_4 alkyl group;

B

R₅₂ expresses a methyl group, an ethyl group, a trifluoromethyl group or a pentafluoroethyl group.

²46. (Amended) A vitamin D₃ compound or a pharmaceutically permissible solvate thereof described in Claim 45¹, wherein, in the above formula (1), R₀₁ and R₀₂ are both hydrogen atoms.

³47. (Amended) A vitamin D₃ compound or a pharmaceutically permissible solvate thereof described in Claim 45¹, wherein, in the above formula (1), R₅₁ is -CONR₅₁₁R₅₁₂ or -COR₅₁₃.

⁴48. (Amended) A vitamin D₃ compound or a pharmaceutically permissible solvate thereof described in Claim 45¹, wherein, in the above formula (1), R₅₁ is -CONR₅₁₁R₅₁₂.

⁵49. (Amended) A vitamin D₃ compound or a pharmaceutically permissible solvate thereof described in Claim 45¹, wherein, in the above formula (1), R₅₁ is -COR₅₁₃.

⁶50. (Amended) A vitamin D₃ compound or a pharmaceutically permissible solvate thereof described in Claim 45¹, wherein, in the above formula (1), R₅₁ is -CONR₅₁₁R₅₁₂, and R₅₁₁ and R₅₁₂ are identical to or different from each other, and they are a methyl group or an ethyl group, or both the members together express an aziridine, pyrrolidine, piperidine or morpholino ring in cooperation with the nitrogen atom to which they are bonded.

⁷51. (Amended) A vitamin D₃ compound or a pharmaceutically permissible solvate thereof described in Claim 45¹, wherein, in the above formula (1), R₅₁ is COR₅₁₃, and R₅₁₃ is a methyl group or an ethyl group.

⁸52. (Amended) A vitamin D₃ compound or a pharmaceutically permissible solvate thereof described in Claim 45¹, wherein, in the above formula (1), R₅₂ is a methyl group.

Amendment Under 37 C.F.R. § 1.111
U.S. Application No. 10/035,211

B1
only
9 ~~53~~. (Amended) A pharmaceutical composition comprising a vitamin D₃ compound or pharmaceutically permissible solvate thereof described in Claim ~~45~~¹, and a pharmaceutically permissible carrier.

Please add the following new claims:

B2
10 ~~54~~. (New) A method for treating an inflammatory respiratory disease comprising administering to a subject a therapeutically effective amount of a vitamin D₃ compound according to claim ~~45~~¹.

11 ~~55~~. (New) A method for treating an inflammatory respiratory disease according to claim ~~54~~¹⁶, wherein the inflammatory respiratory disease is at least one inflammatory respiratory disease selected from the group consisting of acute upper airway infection, chronic sinusitis, allergic rhinitis, chronic lower airway infection, pulmonary emphysema, pneumonia, bronchial asthma, tuberculosis sequela, acute respiratory distress syndrome, cystic fibrosis and pulmonary fibrosis.

12 ~~56~~. (New) A method of treating an inflammatory respiratory disease according to claim ~~55~~¹¹, wherein the inflammatory respiratory disease is at least one acute upper airway infection selected from of the group consisting of common cold, acute pharyngitis, acute rhinitis, acute sinusitis, acute tonsillitis, acute epiglottitis and acute bronchitis.

13 ~~57~~. (New) A method of treating an inflammatory respiratory disease according to claim ~~56~~¹², wherein the inflammatory respiratory disease is at least one chronic lower airway infection selected from of the group consisting of chronic bronchitis, diffuse panbronchiolitis and bronchiectasis.

Amendment Under 37 C.F.R. § 1.111
U.S. Application No. 10/035,211

B2
contd
~~14~~ 58. (New) A method of treating a disease selected from the group consisting of malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, and dermatitis, comprising administering to a subject a therapeutically effective amount of a vitamin D₃ compound according to claim ~~45~~ 1

~~15~~ 59. (New) A method of treating hypercalcemia attributable to vitamin D excess, comprising administering to a subject a therapeutically effective amount of a vitamin D₃ compound according to claim ~~45~~ 1

~~16~~ 60. (New) A method of treating hypoparathyroidism, comprising administering to a subject a therapeutically effective amount of a vitamin D₃ compound according to claim ~~45~~ 1

~~17~~ 61. (New) A method of treating a metabolic disorder of cartilage, comprising administering to a subject a therapeutically effective amount of a vitamin D₃ compound according to claim ~~45~~ 1
